Herbalife (HLF) Free Cash Flow: A Levered Cash Story

FCF Performance Summary

Market Cap: $1.19B  |  Enterprise Value: $2.83B  |  Price: $11.51 (as of August 6, 2026)

Cash Generation Quality

FCF exceeded adjusted net income in 2025 at a 115% conversion ratio, and is guided toward 127% for 2026 — a pattern typical of a low-capital-intensity business where depreciation and amortization, at $121 million in 2025, run ahead of the $80 million spent on capital expenditures. The GAAP-to-adjusted bridge is honest rather than aggressive: goodwill is $101 million against a $2.8 billion balance sheet, acquisitions have been essentially nil, and the one year that needs a caveat is 2024, when GAAP net income of $254 million was flattered by an $85 million tax benefit and a $230 million deferred tax swing while FCF fell to its $163 million low. That divergence — GAAP earnings up, cash down — is the cleanest illustration in the dataset of why this analysis anchors on cash rather than reported earnings.

Stock-based compensation is not doing any hidden work here. At $44 million, SBC ran 17% of 2025 FCF and has fallen by more than half in absolute dollars since 2018's $99 million. Deducting it in full still leaves $209 million of owner-economic FCF, a 17.5% yield on the current market cap — one of the rare cases where subtracting SBC in full does not change the underlying quality conclusion.

FCF-to-OCF conversion bottomed at 56% in 2022, when capital expenditures peaked at $156 million, and has since recovered to 76% in 2025 as capex fell by nearly half. The constraint that keeps overall cash conversion from EBITDA lower than the OCF ratio suggests is interest: $206 million of interest expense consumed 31% of $658 million in adjusted EBITDA in 2025. Strip the interest line out and the underlying business converts roughly 70% of EBITDA to free cash flow — a healthy figure obscured by the capital structure sitting on top of it.

FY2025 Capital Allocation Breakdown

The allocation pattern in 2025 is the mirror image of 2018–2022, when the company spent $2.85 billion repurchasing stock at a spend-weighted average price near $46 per share while net debt rose by $929 million over the same five years — a program that, measured against today's $11.51 share price, destroyed more shareholder value than Herbalife's entire current market capitalization. Buybacks have run under $10 million a year since 2023, roughly enough to offset SBC dilution and nothing more, while essentially all discretionary cash has gone to debt reduction. That is now the correct use of the cash, and it is the allocation decision this analysis weights most heavily in assessing management going forward.

8-Year FCF Trend Analysis (FY2018–FY2025)

The eight-year series is not a smooth decline; it is volatile through 2021, falls hard into a 2024 trough, and then inflects — and distinguishing a genuine inflection from a one-year bounce is the central analytical task here.

FY2018  ██████████████████████████████  $564M
FY2019  ██████████████████               $351M   (-38%)
FY2020  ███████████████████████████      $517M   (+47%)
FY2021  ████████████████                 $309M   (-40%)
FY2022  ██████████                       $196M   (-37%)
FY2023  ████████████                     $222M   (+13%)
FY2024  █████████                        $163M   (-27%)
FY2025  ██████████████                   $253M   (+55%)

  7Y CAGR (2018–2025): -10.8%  |  3Y CAGR (2022–2025): +8.9%  |  8-Yr Avg: $322M

Trend Narrative

From 2018 through 2021, revenue was roughly stable to growing — 2021 marked an all-time high at $5.8 billion — but free cash flow swung sharply anyway, because the company was simultaneously funding $2.7 billion of buybacks with borrowed money. Net debt climbed from $1.25 billion to $2.16 billion across this window even as operations generated $1.6 billion of cumulative FCF, and interest expense began its climb from $132 million toward the $200 million-plus range it would settle into. The revenue line looked fine; the capital structure being built underneath it was the actual story of this phase.

2022 through 2024 is the trough. Operating margin fell from 14.0% in 2018 to 7.0% in 2023 as SG&A held near $1.9 billion against a revenue base that had started shrinking — 2024 revenue of $4.99 billion was 14% below the 2021 peak, driven overwhelmingly by China, where revenue collapsed from $1.0 billion in 2018 to a fraction of that by 2024 as the market's economics deteriorated structurally. Capital expenditures peaked at $156 million in 2022, compounding the squeeze, and interest expense reached $206 million by 2024 — a permanent claim on cash that the 2018–2022 buyback program had created and that operating performance now had to carry through its weakest years.

2025 and the first half of 2026 are where the data starts to argue for an inflection rather than continued decay. FCF rose 55% to $253 million in 2025 and cash from operations reached $147 million in the first half of 2026 alone, up 52% year over year according to the company's own reporting. Capital expenditures fell to $80 million in 2025 with 2026 guidance of $50–70 million, and an April 2026 refinancing swapped $849 million of 12.25% notes for $800 million at 7.75%, cutting annual interest by roughly $38 million. None of that changes the fact that the growth driving 2026's revenue guide is priced-led — North America grew 20% in the second quarter of 2026 on a 2% volume decline — which is a different and more fragile kind of growth than volume expansion, particularly in a distributor-driven sales model.

Operating Cash Flow and Net Income Context

Herbalife does not break out depreciation and amortization as a standalone line in every period, but the 2025 figure of $121 million against $80 million of capex implies a CapEx/D&A ratio near 66% — the company is spending meaningfully less on new capital than it is depreciating on its existing base. Management describes the recent capex underspend as "good practices" rather than a financial constraint, and the pattern is consistent with a maturing, asset-light distribution business rather than one starving its physical footprint. It is nonetheless a ratio worth tracking: a CapEx/D&A figure that stays well under 100% for several more years would start to raise a legitimate reinvestment-adequacy question rather than just reflect capital discipline.

Capital Expenditure Profile

Capital intensity has essentially halved, from 3.0% of revenue at the 2022 peak to a guided 1.1% for 2026, and that decline mechanically explains most of the FCF/OCF conversion recovery documented above. One caveat from the 2026 guidance: the reported capex line of $50–70 million excludes $35–55 million of capitalized SaaS implementation costs that are running through the balance sheet rather than the capex line, meaning the true investment run rate is closer to $105 million than the headline figure suggests. That does not change the FCF calculation, which uses reported capex, but it is worth knowing before treating the capex decline as pure margin expansion.

FCF Quality Score: 5/10 — Medium Quality

Derived FCF Quality Score: 5/10 — clean, verifiable cash conversion and a genuine recent capital-allocation correction are offset by a seven-year FCF decline whose peak-to-trough magnitude (a 71% fall from $564 million to $163 million) exceeds the threshold this framework treats as material volatility, landing the score at the midpoint of the Medium Quality band rather than higher or lower within it.

The accounting quality supporting the score is unusually clean for a company this leveraged: CFO minus capex reconciles to Herbalife's reported FCF line across all eight historical years with a zero gap, there are no capitalized contract costs or serial acquisition amortization inflating the figures, and SBC at 15–17% of FCF is both modest and shrinking. Layered on top of that is a real change in capital discipline — buybacks that ran at $2.85 billion from 2018–2022 have been effectively zero since 2023, and 81% of 2025's free cash flow went to debt reduction rather than financial engineering. The April 2026 refinancing, which cut $38 million of annual interest and pushed the debt wall to 2033, is the clearest evidence that management is now managing the balance sheet rather than the share count.

What holds the score at the midpoint rather than higher is the trajectory itself. A 10.8% compound annual FCF decline across seven years is a large number to explain away, and the 2025–2026 recovery is not yet volume-confirmed: revenue growth in the company's largest market, North America, was entirely a function of price increases against falling unit volumes in the second quarter of 2026. In a multi-level marketing structure, the distributor network is simultaneously the sales force and the customer base, so extracting margin through price rather than volume growth is a strategy that transfers economics away from the same people who drive future sales — a dynamic that shows up in the numbers only with a lag.

The two risks that could push the score lower from here are distinct from each other. First, GLP-1 substitution in weight management, which is 55% of Herbalife's revenue and down 19% since 2021 — a decline consistent with pharmacological substitution, though also consistent with post-pandemic normalization and the China collapse, and one that management did not address on its most recent earnings call. Second, the two debt tranches — $274 million of 4.25% convertible notes due 2028 and $597 million of 4.875% senior notes due 2029 — that were priced in a materially lower rate environment; refinancing roughly $871 million from an average of 4.5% to something closer to 8% would add about $30 million of annual interest, equal to roughly 10% of current FCF, making continued debt paydown between now and those maturities a necessity rather than a discretionary deleveraging choice.

Forward Outlook: Key Scenarios

The variable that determines which scenario plays out is not a cash flow question at all — it is whether Herbalife's distributor network can sustain price-led revenue growth without the volume attrition that would eventually follow it, and whether the weight management segment stabilizes or continues eroding against GLP-1 competition.

Scenario values are illustrative only, derived from an exit-yield framework applied to steady-state FCF assumptions, and do not constitute forecasts or price targets.

Catalysts to Monitor

Volume trends in North America and EMEA over the next two quarters are the single most important data point. The current growth algorithm — 20% North America revenue growth on a 2% volume decline in Q2 2026 — cannot be judged sustainable or not from one quarter. Two consecutive quarters of actual volume growth, rather than price-driven revenue growth, would meaningfully support the recovery case; a return to volume declines once the current price increases annualize would support the opposite.

Net leverage progress against the stated sub-2.0x year-end 2026 target, and specifically whether a buyback restart happens before leverage clears 1.5x. Given the 2018–2022 record, a buyback restart at elevated leverage would be the clearest possible signal that the capital allocation discipline of the past three years has not actually taken hold.

The CFO transition at year-end 2026. John DeSimone, who executed both the shift away from buybacks and the April 2026 refinancing, is being succeeded by Scott Schaefer. Whether the debt-paydown priority survives that handover is a governance question with direct cash-flow consequences.

Any explicit management commentary on GLP-1 competitive dynamics in weight management, which remains conspicuously absent from recent earnings calls despite the segment's 19% decline since 2021 and its 55% share of total revenue.

Overall Assessment: HLF FCF Quality Score 5/10

Herbalife's free cash flow is real and cleanly accounted for — the reconciliation between operating cash flow, capital expenditures, and reported FCF holds with zero gap across eight consecutive years, which is not something that can be said of every company screening at a 21% FCF yield. What the cash flow arithmetic cannot settle is whether that yield reflects a market mispricing a business in the early stages of a genuine turnaround, or a market correctly pricing continued structural decline in a distributor-dependent sales model facing both a shrinking China business and unquantified GLP-1 substitution risk in its largest segment.

The multi-year data makes the risk explicit rather than hiding it: a 71% peak-to-trough FCF decline from 2018 to 2024, driven roughly equally by margin compression and a debt-funded buyback program that added $929 million of net debt while destroying more market value than the company is currently worth. The 2025–2026 recovery is real on a cash basis — capex has halved, interest expense has been cut through refinancing, and operating cash flow was up 52% in the first half of 2026 — but it rests on price increases against falling volumes, which is a fragile foundation in a multi-level marketing structure where the distributor base is also the customer base.

A 5/10 FCF Quality Score reflects a business with genuinely clean cash generation and a management team now allocating capital correctly, held back from a higher score by a still-unresolved question about revenue durability that the cash flow statement alone cannot answer. The FCF Quality Score methodology behind this rating is detailed in Assessing FCF Quality. For context on what a 21% trailing yield means relative to typical benchmarks, see What Is a Good Free Cash Flow Yield? — on FreeCashFlow.org's own B-series screener, HLF currently shows a 29.04% FCF yield, roughly 6.5 points above the Consumer Staples sector median, using a trailing-twelve-month calculation consistent with the ~27% LTM figure cited above. For the mechanics of the FCF/net-income divergence discussed throughout this piece, see Free Cash Flow vs. Net Income. Current screener data on HLF, including peer comparisons across Consumer Staples, is available at the FCF Screener.

⚠️ Disclaimer: This analysis is for educational and informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any recommendation to buy, sell, or hold any security. All financial data is sourced from publicly available SEC filings and is believed to be accurate as of the analysis date but has not been independently audited. Actual results may differ materially from any scenario estimates presented. FCF calculations use operating cash flow minus capital expenditures; alternative definitions may yield different results. Always conduct your own due diligence and consult a licensed financial advisor before making investment decisions. Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal.

Data Sources

• Herbalife Ltd. Annual Reports (10-K): FY2018–FY2025 — SEC EDGAR XBRL (data.sec.gov)
• Herbalife Q2 2026 Earnings Release and 10-Q (August 5, 2026); Q2 2026 earnings call transcript
• Bloomberg Company Financials (HLF US Equity), pulled August 7, 2026, for historical actuals and consensus estimate cross-check; market data as of August 6, 2026 close